FOLH1 and hematologic disorder: Unlike CD-19- or BMAC-directed CAR-T cell therapy for hematologic malignancies, CAR-T cells directed against solid tumor antigens, such as PD-L1 and prostate-specific membrane antigen (PSMA), have had less clinical success due to obstacles pertaining to the suppressive nature of the tumor microenvironment and therapy persistence within the tumor (306).